The Exchange has sought clarification from Aurobindo Pharma today with reference to news displayed - in MONEYCONTROL on February 01, 2016 : ‘unit 3 and unit 7 inspected USFDA,UNIT 7 sees few observations’.
The above information is a part of company’s filings submitted to BSE.